Epithalon: experimental longevity peptide (Epitalon / AEDG)
A tiny synthetic peptide derived from the pineal gland, studied in Russia for anti-aging effects including telomere lengthening; not an approved drug, experimental research chemical only.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
FDA-tracked compound — synthesized for clinical/research use
Fork this card to add platform evidence →
FDA-tracked (reclassified Category 1, Feb 2026) — preclinical/clinical bioassay data exists
Fork this card to add platform evidence →
What this is
Epithalon (also spelled Epitalon, and sometimes Epithalone) is a synthetic four-amino-acid peptide — alanine-glutamate-aspartate-glycine, AEDG — developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in Russia during the 1980s and 1990s. It is the chemically defined "short" analog of epithalamin, a crude bovine pineal gland extract the same group had worked on since the 1970s. The peptide is best known for in vitro reports of telomerase activation and telomere elongation in human somatic cells, and for being marketed through research-chemical channels as a longevity compound — claims whose evidence base sits almost entirely inside one Russian research program (Khavinson and colleagues, Bulletin of Experimental Biology and Medicine, 2003; Araj and colleagues, International Journal of Molecular Sciences, 2025).
Epithalon is not approved as a medicine in any Western jurisdiction. It is sold as a research chemical and is not, despite frequent confusion, a registered Russian prescription medicine in the same sense as Cerebrolysin or Selank.
History
The Khavinson program at the St. Petersburg Institute of Bioregulation and Gerontology pursued the idea that short fragments of tissue-derived peptide extracts could regulate organ-specific aging — what the group termed "peptide bioregulators". Epithalamin, the crude pineal extract, was the starting material. AEDG was the synthesized tetrapeptide they identified as the active short-fragment representative; later work in the same lineage reported isolation of the AEDG sequence from the polypeptide complex of the pineal gland itself (Khavinson and colleagues, Bulletin of Experimental Biology and Medicine, 2017).
The foundational telomerase-activation paper was published by the Khavinson lab in 2003 — the report that AEDG could induce telomerase activity and telomere elongation in cultured human somatic cells (Khavinson and colleagues, Bulletin of Experimental Biology and Medicine, 2003). The same year, a separate Khavinson-program paper in Neuroendocrinology Letters reported that combined pineal and thymus peptides were associated with reduced mortality in elderly Russian subjects (Khavinson and colleagues, 2003).
Subsequent work over two decades within the same program covered rodent lifespan studies, melatonin and pineal physiology under varied lighting regimes, neuroendocrine modulation, and a small clinical report in retinitis pigmentosa. A 2025 review in International Journal of Molecular Sciences (Araj and colleagues, 2025) summarizes the now ~25-year literature; the foundational claims have not been independently replicated by major Western academic laboratories.
What it does
In cell culture, Epithalon is reported to upregulate hTERT (telomerase reverse transcriptase) expression and elongate telomeres in human somatic cells, including cells that had reached replicative senescence in vitro (Khavinson and colleagues, Bulletin of Experimental Biology and Medicine, 2003). A 2025 independent in vitro study reports telomere lengthening across human cell lines, identifying both telomerase upregulation and contributions from the alternative-lengthening-of-telomeres (ALT) pathway depending on cell line (Al-dulaimi and colleagues, Biogerontology, 2025).
The peptide is also described as modulating pineal gland function and melatonin-related signaling — biology consistent with its origin as an epithalamin analog. In rat pinealocyte culture, Epithalon has been reported to stimulate AANAT (a key enzyme in melatonin biosynthesis) and the pCREB transcription factor, increasing melatonin output (Khavinson lab, Bulletin of Experimental Biology and Medicine, 2012). In animal work, intranasal AEDG affects neuronal activity in the rat neocortex, and combined melatonin/Epithalon protocols modify hypothalamic regulation and pineal-axis dynamics across lighting conditions and aging models (Khavinson-program literature). Recent independent in vitro and animal work has reported additional effects: protection of post-ovulatory mouse oocytes from aging-related damage (Yue and colleagues, Aging, 2022), enhancement of bovine oocyte maturation and post-thaw embryo development tied to telomerase activation (Ullah and colleagues, Life Sciences, 2025), and antioxidant-mediated wound-healing effects in an in vitro model of diabetic retinopathy (Gatta and colleagues, Stem Cell Reviews and Reports, 2025).
The molecular basis for how a four-amino-acid peptide upregulates hTERT expression has not been resolved at the biochemical level; in vivo dose-response and mechanism specificity, independent of the originating lab, are not established.
Evidence
- Human: Weak. The most cited human study is a Russian elderly cohort (Khavinson and colleagues, Neuroendocrinology Letters, 2003) that combined Epithalon with thymus-derived peptides over multi-year follow-up and reported reduced all-cause mortality — but because the intervention combined two peptides, Epithalon's individual contribution cannot be isolated, and the study was unblinded and single-program. A small clinical report describes retinal improvement in retinitis pigmentosa patients (Khavinson-program literature, Bulletin of Experimental Biology and Medicine, 2002). A multi-year study in elderly patients with coronary heart disease is associated with the same program. No blinded randomized controlled trial in any longevity, anti-aging, or telomere-maintenance endpoint has been completed.
- Animal: Moderate, but concentrated in one program. Lifespan extension has been reported in multiple rodent strains and in Drosophila; pineal/melatonin and neuroendocrine effects have been characterized across lighting and aging models. Carcinogenesis findings are mixed and methodologically inconsistent — see Safety signals below.
- In vitro: Moderate. The 2003 telomerase/telomere-elongation finding (Khavinson and colleagues, 2003) is the most cited result. The 2025 Al-dulaimi paper (Biogerontology) provides an independent in vitro replication of telomere lengthening across human cell lines, identifying both telomerase-upregulation and ALT components. Chromatin remodeling and stimulation of neurogenesis-related gene expression have also been reported (Khavinson-program literature, Molecules, 2020).
The 2025 International Journal of Molecular Sciences overview (Araj and colleagues, 2025) is the most useful single entry point to the published Epithalon literature; it summarizes 25 years of in vitro, in vivo, and in silico work.
Mechanism
Telomerase activation (hTERT upregulation). Epithalon is reported to upregulate hTERT expression in cultured human somatic cells, promoting telomere elongation and reactivating telomerase in cells that had reached replicative senescence in vitro (Khavinson and colleagues, Bulletin of Experimental Biology and Medicine, 2003). The 2025 Al-dulaimi paper (Biogerontology) reports elongation in human cell lines occurring via telomerase upregulation in some lines and via the ALT pathway in others — adding mechanistic complexity to the original single-mechanism framing.
Pineal and melatonin modulation. As an analog of epithalamin, Epithalon is proposed to influence pineal gland function and normalize melatonin secretion. In rat pinealocyte culture, Epithalon has been reported to stimulate AANAT and pCREB and to increase melatonin output (Khavinson lab, 2012). Animal studies across multiple aging and lighting conditions support these neuroendocrine effects.
Epigenetic gene regulation. The AEDG sequence has been proposed to interact with DNA regulatory regions and modulate gene expression through epigenetic mechanisms; the program reports stimulation of neurogenesis-related gene expression and protein synthesis (Khavinson lab, Molecules, 2020). The molecular basis for how a four-amino-acid peptide achieves specific hTERT upregulation in vivo remains unresolved.
Dual biology of telomerase. Telomerase activation is also the mechanism by which cancer cells achieve replicative immortality. One rat colon carcinogenesis study (Anisimov-program literature, 2003) produced findings that complicate any simple "more telomerase is better" framing. The net in vivo effect of exogenous Epithalon on cancer risk has not been resolved.
Myths and misconceptions
- "Epithalon has been proven to extend human lifespan." It has not. The lifespan claims come from a single Russian elderly cohort that combined Epithalon with thymus peptides, plus rodent studies, all from the Khavinson research program. No blinded RCT for any longevity endpoint has been completed; longevity science as a field does not recognize Epithalon as a proven geroprotective agent.
- "Telomerase activation is unambiguously anti-aging." Telomerase is also the mechanism by which cancer cells achieve replicative immortality. One Khavinson-program rat study found increased colon carcinogenesis in Epithalon-treated animals (Anisimov-program literature, 2003). The net effect of exogenous telomerase activation on human cancer risk is unresolved.
- "Epithalon is a registered medicine in Russia." It is not. The Khavinson group's affiliated bioregulator ecosystem includes dietary-supplement-style products and investigational protocols, but Epithalon does not hold prescription-medicine approval comparable to Cerebrolysin or Selank. Russian origin of a research program is not equivalent to Russian medical approval.
- "It's just four amino acids — it has to be safe." Small size does not imply safety. If the claimed mechanism is correct, Epithalon modulates cell-cycle and senescence biology, which is precisely where serious safety questions arise. Short peptides can have strong biological effects; safety must be established by data, not inferred from molecular weight.
- "Research-chemical Epithalon is equivalent to the Khavinson clinical preparation." A 2014 analytical study in Drug Testing and Analysis identified Epitalon in two illegal pharmaceutical preparations — and independent testing of peptide products in this market has repeatedly found discrepancies between label and content. Inferring efficacy from Khavinson-program preparations to an arbitrary research-chemical product is not a safe extrapolation.
Known effects
- Telomerase activation and telomere elongation in cultured human somatic cells — In vitro; limited independent replication emerging (Al-dulaimi and colleagues, 2025).
- Melatonin synthesis modulation in pinealocytes — Preclinical (rat pinealocyte culture); plausible given pineal lineage.
- Neurogenesis-related gene expression stimulation — Preclinical; proposed epigenetic mechanism (Khavinson program).
- Retinal protection — Preclinical (rodent), with one small Khavinson-program clinical report in retinitis pigmentosa patients.
- Lifespan extension in rodents and Drosophila — Preclinical; single research program; not independently replicated.
- Reduced all-cause mortality in elderly humans — Very weak. Single unblinded Russian cohort; combination therapy with thymus peptides; effect not isolable to Epithalon; not independently replicated.
- Oocyte and embryo protection — Preclinical (Yue and colleagues, 2022; Ullah and colleagues, 2025).
- Wound healing support in a diabetic retinopathy model — In vitro only (Gatta and colleagues, 2025).
Safety signals
Human data are very limited. The Khavinson program describes Epithalon as generally well-tolerated in short-course Russian clinical use, with injection-site reactions as the most commonly noted adverse event. No systematic human safety trial under modern GCP standards is identified. Short-course tolerability does not establish long-term safety.
Animal carcinogenesis signal — colon. A Khavinson-program rat study reported increased colon carcinogenesis in Epithalon-treated animals, examining proliferative activity and apoptosis in colon tumors and mucosa (Anisimov-program literature, 2003). Other carcinogenesis studies from the same program have reported reductions or null results in different tumor models (bladder, spontaneous tumors in SAM mice, female C3H/He mice); the picture is mixed, single-program, and methodologically inconsistent.
Theoretical cancer risk. Published literature within the program acknowledges telomerase activation as "a double-edged sword". Promoting telomerase activity in cells with oncogenic potential is a serious mechanistic concern that has not been adequately studied in humans receiving Epithalon. Long-term human pharmacovigilance data for malignancy outcomes are essentially absent.
Pharmacokinetics. The intact tetrapeptide's plasma half-life is described as on the order of minutes; downstream effects on melatonin signaling are reported to persist longer. Absorption, distribution, and clearance in humans across administration routes are not characterized in controlled pharmacokinetic studies.
Regulatory status
- US (FDA): Not approved for any indication. Epithalon was removed from the FDA's 503A category 2 compounding nominations list on April 22, 2026 (nominations withdrawn). The FDA has indicated it will consult the Pharmacy Compounding Advisory Committee (PCAC) on July 24, 2026 regarding Epitalon acetate and Epitalon (free base). Pending PCAC action, Epithalon remains an unapproved new drug for US compounding purposes — the 503A removal does not constitute approval.
- Russia: Not a registered prescription medicine. Some Khavinson-program bioregulator products exist as dietary supplements or investigational therapies, but Epithalon does not hold prescription approval comparable to Cerebrolysin or Selank.
- EU (EMA), UK (MHRA), Canada (Health Canada), Australia (TGA): No marketing authorization.
- WADA: Not specifically named on the Prohibited List. As an unapproved substance for human therapeutic use, WADA S0 (substances not approved by any governmental regulatory health authority) is the catch-all category most likely to apply; athletes subject to WADA code should treat it as prohibited until clarified with their anti-doping authority.
Open questions
- Independent Western replication. As of 2026, no major Western academic laboratory has independently reproduced the core human-mortality findings under modern trial methodology. The Al-dulaimi 2025 in vitro report (Biogerontology) is one of the first independent telomere-elongation replications; in vivo replication is still absent.
- Blinded randomized controlled trials. None has been completed in humans for any longevity, anti-aging, or telomere-maintenance endpoint.
- Epithalon-specific contribution in human cohort data. The most cited human mortality study combined Epithalon with thymus-derived peptides; Epithalon's individual contribution cannot be isolated from that design.
- Long-term cancer safety. Given the telomerase-activation mechanism and the rat colon carcinogenesis signal, pharmacovigilance for malignancy outcomes is a critical gap. Short observational windows are insufficient.
- Pharmacokinetics in humans. Absorption, distribution, half-life, and clearance across administration routes have not been characterized in controlled studies.
- Mechanism resolution. The molecular basis for how a tetrapeptide upregulates hTERT — direct receptor binding, transcription-factor interaction, epigenetic modulation, or otherwise — has been proposed but not resolved at the biochemical level. In vivo specificity at claimed dose ranges has not been independently confirmed.
- Research-chemical product equivalence. Whether observations from Khavinson-program preparations generalize to research-chemical products with variable purity is unestablished (Thevis and colleagues, Drug Testing and Analysis, 2014).
Related peptides
- N-Acetyl Epithalon Amidate (NAEA) — A chemically modified Epithalon variant with N-terminal acetyl cap and C-terminal amide, marketed on the premise of improved peptidase resistance. There is no published head-to-head pharmacokinetic or clinical comparison of the amidate variant versus plain Epithalon; the claimed advantage rests on peptide-chemistry reasoning, not on data.
- Epithalamin — The original crude bovine pineal extract from which AEDG was derived; the parent material of the Khavinson pineal-peptide program.
- GHK-Cu, Selank, Semax, Cerebrolysin — Other short peptides associated with Russian bioregulator or neuropeptide research traditions. Listed for orientation; mechanisms and evidence bases differ substantially from Epithalon and these compounds are not interchangeable.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Does Epithalon work by loosening the chromosomal packaging around the telomerase gene, rather than by directly contacting the enzyme?
If true, doctors could predict which patients or cell types will respond to Epithalon based on a simple genetic test, and could combine it with existing approved drugs to get a stronger effect. This could make future telomere-based therapies far more targeted.
Does Epithalon trigger a DNA-repair shortcut that some tumors already misuse to become immortal?
If Epithalon activates this backup pathway, it would be a serious warning for certain cancer-prone individuals, but would also help researchers understand exactly which people could safely use telomere-lengthening therapies and which should avoid them.
Does Epithalon's effect on cellular aging depend on whether the cell is already under stress from inflammation or oxidative damage?
If this is true, Epithalon could become a targeted therapy for people whose cells age faster because of chronic inflammation, such as those with diabetes or autoimmune disease, while being unnecessary and possibly irrelevant for healthy individuals. That would make clinical trials far cheaper and more likely to succeed.
Is Epithalon helping animals live longer by resetting their daily biological clock rather than by protecting the ends of their chromosomes?
If circadian rhythm restoration is the real mechanism, Epithalon could be repurposed to help shift workers, frequent travelers, and elderly people with fragmented sleep, a huge and underserved population, while also providing a simpler, safer explanation for its effects that could accelerate regulatory approval.
Could Epithalon slip into a slot on the cellular machinery that normally reads chemical tags on chromosomes, thereby changing which genes are turned on?
Finding the exact protein Epithalon latches onto would finally explain decades of inconsistent results and could point to entirely new drug targets for age-related diseases, benefiting researchers developing treatments for conditions like Alzheimer's or muscle wasting.
Would mixing up the order of Epithalon's four building blocks, while keeping everything else identical, destroy its activity?
If order matters, scientists can design slightly modified versions of Epithalon that are more stable in the bloodstream, potentially turning a fragile research chemical into a real drug candidate.
▸full evidence table1 metrics
| metric | value | tool |
|---|---|---|
| ranking score | 0.8403757214546204 | boltz-2 |
▸3-letter notation
▸recipeboltz-2 2.2.1
| parameter | value |
|---|---|
| model | boltz-2 2.2.1 |
| weights | — |
| hardware | vast_v100_32gb |
| mlx version | — |
| python | — |
| random seed | 1 |
| msa strategy | none_monomer |
| runtime | — |
| predicted by | — |
| predicted at | 2026-05-23 |
▸citationbibtex
@peptide{pep00008,
sequence = {AEDG},
target = {anti-aging},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}